Short Interest in CytoMed Therapeutics Limited (NASDAQ:GDTC) Expands By 5.3%

Posted by Donald Scott on Sep 17th, 2024

CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 125,600 shares, a growth of 5.3% from the August 15th total of 119,300 shares. Based on an average trading volume of 65,200 shares, the short-interest ratio is presently 1.9 days. Approximately 2.7% of the shares of the company are sold short.

CytoMed Therapeutics Stock Performance

Shares of NASDAQ:GDTC opened at $1.50 on Tuesday. The company has a current ratio of 14.09, a quick ratio of 14.09 and a debt-to-equity ratio of 0.04. The firm’s 50 day moving average price is $1.74 and its 200-day moving average price is $1.98. CytoMed Therapeutics has a twelve month low of $1.36 and a twelve month high of $5.50.

Analysts Set New Price Targets

Separately, Benchmark reissued a “speculative buy” rating and issued a $5.00 target price on shares of CytoMed Therapeutics in a report on Tuesday, June 11th.

Check Out Our Latest Stock Report on GDTC

About CytoMed Therapeutics

(Get Free Report)

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.